RI
The startup develops a therapeutic monitoring device that provides real-time data on vital signs and symptoms associated with Neonatal Abstinence Syndrome (NAS). This technology enables healthcare professionals to deliver personalized interventions tailored to the specific needs of each patient, improving treatment outcomes for affected neonates.
Updated 3 months ago
Funding
$230K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a therapeutic monitoring device that provides real-time data on vital signs and symptoms associated with Neonatal Abstinence Syndrome (NAS). This technology enables healthcare professionals to deliver personalized interventions tailored to the specific needs of each patient, improving treatment outcomes for affected neonates.